|
End-of-day quote
OTC Markets
2021-07-08
|
5-day change | 1st Jan Change | ||
| 5.090 USD | +23.84% |
|
-.--% | - |
| 09-03 | Chardan Initiates Vyome Holdings at Buy With $3.50 Price Target | MT |
| 08-28 | Vyome Holdings, Inc. Announces CFO Changes | CI |
Company Valuation: ReShape Lifesciences
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Market Cap 1 | 19.42 | 13.41 | - | - |
| Change | - | -30.96% | - | - |
| Enterprise Value (EV) | 19.42 | 13.41 | 13.41 | 13.41 |
| Change | - | -30.96% | 0% | 0% |
| P/E | -0.71x | -2.94x | -2.4x | -2.4x |
| PBR | - | - | - | - |
| PEG | -0x | 0x | -0.1x | 11.45x |
| Capitalization / Revenue | 60.7x | 130x | 44.7x | - |
| EV / Revenue | 0x | 130x | 44.7x | - |
| EV / EBITDA | - | 8.94x | -22x | - |
| EV / EBIT | -0x | -2.81x | -1.64x | -1.03x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -4.86 | -0.65 | -0.7967 | -0.795 |
| Distribution rate | - | - | - | - |
| Net sales 1 | 0.3197 | 0.103 | 0.3 | - |
| EBITDA 1 | - | 1.5 | -0.61 | - |
| EBIT 1 | -10.45 | -4.771 | -8.193 | -12.99 |
| Net income 1 | -10.26 | -4.489 | -7.846 | -12.99 |
| Net Debt | - | - | - | - |
| Reference price 2 | 3.440 | 1.910 | 1.910 | 1.910 |
| Nbr of stocks (in thousands) | 5,644 | 7,019 | - | - |
| Announcement Date | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HIND Stock
- RSLS Stock
- Valuation ReShape Lifesciences
Select your edition
All financial news and data tailored to specific country editions
